Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Simcere Teams Up Again With Bristol-Myers For Co-Development In China

This article was originally published in The Pink Sheet Daily

Executive Summary

After signing a deal in deal in November 2010 for a MET-VEGFR-2 inhibitor, Simcere and BMS switch gears for a CETP inhibitor.

You may also be interested in...



Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity

With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.

Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol

Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds

Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost

European Society of Cardiology Congress abstract for small study suggests Roche's dalcetrapib is safe and works on plaque burden.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS073173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel